C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 123 filers reported holding C4 THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $848,093 | -29.7% | 455,844 | +3.8% | 0.00% | – |
| Q2 2023 | $1,207,137 | -54.3% | 438,959 | -47.8% | 0.00% | – |
| Q1 2023 | $2,640,042 | +56023.3% | 840,778 | +5.5% | 0.00% | -100.0% |
| Q4 2022 | $4,704 | -99.9% | 797,292 | +2.6% | 0.00% | 0.0% |
| Q3 2022 | $6,816,000 | +25.3% | 777,222 | +7.7% | 0.00% | 0.0% |
| Q2 2022 | $5,439,000 | -66.4% | 721,425 | +8.0% | 0.00% | -50.0% |
| Q1 2022 | $16,201,000 | -26.7% | 667,819 | -2.7% | 0.00% | -33.3% |
| Q4 2021 | $22,094,000 | -25.8% | 686,176 | +3.0% | 0.00% | -25.0% |
| Q3 2021 | $29,771,000 | +74.6% | 666,323 | +47.9% | 0.00% | +100.0% |
| Q2 2021 | $17,048,000 | +139.3% | 450,542 | +133.9% | 0.00% | +100.0% |
| Q1 2021 | $7,123,000 | +13.6% | 192,592 | +1.8% | 0.00% | 0.0% |
| Q4 2020 | $6,269,000 | – | 189,251 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |